GSK163929

GSK163929 (compound 122) is an orally active, anti-HIV CCR5 antagonist with low inhibitory potency against hEGR. GSK163929 had no adverse effects in rats at 2000 mg/kg/day (i.v., 7 d) and in dogs at 250 mg/kg/day (i.v., 7 d) [1].

Product Specifications

CAS Number

[716354-04-0]

UNSPSC

12352005

Target

CCR; HIV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gsk163929.html

Smiles

CC1=NC2=C(C=CC=C2)N1C3C[C@H](CC4)N([C@H]4C3)CCC5(C6=CC(F)=CC=C6)CCN(C(C7=CC(S(=O)(NC)=O)=C(F)C=C7Cl)=O)CC5

Molecular Formula

C36H40ClF2N5O3S

Molecular Weight

696.25

References & Citations

[1]Kazmierski WM, et al. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J Med Chem. 2011 Jun 9;54 (11) :3756-67.